Bone News and Research

RSS

CryoLife to acquire Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, and Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of patients with refractory angina resulting from diffuse coronary artery disease, today announced that the boards of directors of both companies have approved a definitive agreement under which CryoLife will acquire all of the outstanding shares of Cardiogenesis for $0.457 per share.

29 Mar 2011

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.

29 Mar 2011

Emory surgeons perform first hand transplant in college student

Transplant and reconstructive surgeons from Emory University Hospital announced today at a news conference that they have successfully performed a rare complete hand transplant on 21-year-old Linda Lu, a college student from Orlando, Fla. This is a first for the Atlanta Hospital.

29 Mar 2011

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.

29 Mar 2011

MolecularMD and ARIAD collaborate to develop and commercialize CML, ALL diagnostic test

ARIAD Pharmaceuticals, Inc. and MolecularMD Corporation today announced an exclusive collaboration agreement in which MolecularMD will develop and commercialize a companion diagnostic test to identify the T315I mutation of the BCR-ABL gene in patients with chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia.

28 Mar 2011

Artimplant's Artelon CMC Soft receives European CE-mark approval

In collaboration with Small Bone Innovations, Artimplant has developed a new product in the Artelon Spacer range with a similar user-friendly textile design to Artelon Tissue Reinforcement.

28 Mar 2011

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program.

25 Mar 2011

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology.

25 Mar 2011

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Protelos has significantly greater bone-forming activity than the commonly prescribed bisphosphonate, alendronate, according to results of the largest-ever biopsy study in post-menopausal women presented today at the European Congress on Osteoporosis and Osteoarthritis in Valencia.

25 Mar 2011

$Falls history improves accuracy of fracture prediction models$

Falls history improves accuracy of fracture prediction models

Researchers from the MRC Lifecourse Epidemiology Unit in Southampton, UK, have presented a new study that shows how the inclusion of falls history, in addition to clinical risk factors (CRFs) and bone mineral density (BMD) values, would greatly improve the accuracy of fracture prediction models. The research findings were presented today at the European Congress on Osteoporosis & Osteoarthritis in Valencia, Spain.

25 Mar 2011

Electromagnetic radiation from cellular phones may affect bone strength

Electromagnetic radiation from cellular phones may adversely affect bone strength, suggests a study in the March Journal of Craniofacial Surgery. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

25 Mar 2011

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that its specially formulated ischemic adult allogeneic mesenchymal stem cells have been successfully used to treat the first patient in an ischemic stroke study conducted at the University of California, San Diego.

25 Mar 2011

BrainStorm provides review of recent accomplishments for shareholders, investors

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.

25 Mar 2011

Columbia University, Sanofi-aventis collaborate to develop innovative diabetes medicines

Sanofi-aventis announced today a research collaboration with Columbia University Medical Center for the development of innovative diabetes medicines.

25 Mar 2011

Study: Surgeon enthusiasm linked to high spinal procedure rates

Surgeons in some areas are more likely to recommend surgery for low back problems—and those differences in "surgeon enthusiasm" are a major factor driving regional variations in spinal surgery rates, suggests a study in the March 14 issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

25 Mar 2011

Quantum dots allow stem cell therapy monitoring for brain injury

A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

25 Mar 2011

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Tarsa Therapeutics today announced that the Phase III ORACAL trial of its oral recombinant salmon calcitonin in the treatment of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, positive top-line results.

25 Mar 2011

Experts to present latest advances in bone research at annual European meeting

Today, the European Congress on Osteoporosis and Osteoarthritis opened in Valencia, Spain with some 4000 international participants. The Congress is the major annual European meeting in the bone field and attracts clinicians, specialists and bone experts from around the world. ECCEO11-IOF continues until March 26th at Valencia's Palacio de Congresos.

24 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

New study provides insights into epiboly mechanisms linked with wound healing, cancer

Avian embryos could join the list of model organisms used to study a specific type of cell migration called epiboly, thanks to the results of a study published this month in the journal Developmental Dynamics.

24 Mar 2011

Bone News and Research

CryoLife to acquire Cardiogenesis

Onyx plans to expand carfilzomib Phase 3 European trial in patients with myeloma

Emory surgeons perform first hand transplant in college student

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

MolecularMD and ARIAD collaborate to develop and commercialize CML, ALL diagnostic test

Artimplant's Artelon CMC Soft receives European CE-mark approval

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Falls history improves accuracy of fracture prediction models

Electromagnetic radiation from cellular phones may affect bone strength

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

BrainStorm provides review of recent accomplishments for shareholders, investors

Columbia University, Sanofi-aventis collaborate to develop innovative diabetes medicines

Study: Surgeon enthusiasm linked to high spinal procedure rates

Quantum dots allow stem cell therapy monitoring for brain injury

Positive results from Tarsa's oral calcitonin Phase III trial against postmenopausal osteoporosis

Experts to present latest advances in bone research at annual European meeting

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

New study provides insights into epiboly mechanisms linked with wound healing, cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News